HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Watch: Next Steps Re Controversial CMR Ban Approach, Fragrance Allergens Labeling

This article was originally published in The Rose Sheet

Executive Summary

EU sources update Rose Sheet on contentious initiatives to cement the Commission’s pathway for banning carcinogenic, mutagenic or reprotoxic substances in cosmetics and to promote fragrance allergen awareness and risk management.

You may also be interested in...



IFRA’s 49th Amendment To Safety Standards Coming Soon With QRA2 Updates

Notification may come within weeks for the 49th Amendment to the International Fragrance Association’s Code of Practice, which will update safe use standards for fragrance materials based on a revised quantitative risk assessment framework that uses a new aggregate exposure model for dermal sensitizers, among other changes. IFRA has been working closely on the issue of fragrance allergens with the European Commission.

'Secrets, Secrets, Are No Fun': California’s Fragrance Transparency Bill Heads For Senate Vote

The Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2019 has cleared key Senate committees, including Appropriations, and is now up for a third read on the Senate floor.

Cosmetics Europe Strategizing To Defend Ingredients Flagged As Endocrine Disruptors, CMRs

Clarification of requirements and a “demanding” timeline for industry’s defense of cosmetic ingredients identified as potentially carcinogenic, mutagenic or reprotoxic, and the Commission’s forthcoming list of potential endocrine disruptors in cosmetic products, are among challenges facing Cosmetics Europe in 2019 and beyond.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS121711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel